Cellink AB (publ) provided sales guidance for the third quarter of 2020. The COVID-19 pandemic continues to restrict mobility around the world and complicate demonstrations of the company's instruments. The company has continued to see good demand for the company's products but has reason to expect declining sales towards the end of the third quarter as a result of the pandemic. At the same time, the company sees new revenue streams from the transition in production to qPCR instruments and AlcoGel. In order to deal with temporary revenue shortfalls, the company has implemented short-term lay offs in parts of the Group.